By Scott Gottlieb (original source Health Affairs)
“In recent years, considerable bipartisan Congressional action, leadership from both Democratic and Republican administrations, and broad-based multistakeholder collaborations have focused on improving the tools and regulatory processes at the Food and Drug Administration (FDA), other government agencies, and public-private collaborations to support more efficient and timely development of new medical technologies. Enhanced funding through user fees and the bipartisan Twenty-First Century Cures legislation have supported a robust and better-resourced FDA and enabled science-driven collaborations in a range of areas including innovative clinical trials, “patient-focused” drug development, and greater clarity around standards for regulatory approval of new technologies.”
Click here to read more
Edward Fishman: How the Strait of Hormuz changes economic warfare
By strangling the waterway, Iran retaliated against the US and eased some financial sanctions. In this episode of The Big View Edward Fishman, senior fellow…
Thought Leader: Edward Fishman
Erika Ayers Badan Launches Mule Media
Say Hello to Mule Media. Mule Media is a women’s community company. Our goal is to support and serve women by meeting them where they’re…
Thought Leader: Erika Ayers Badan
Marc Short & Mark Halperin: Midterms Tough Ahead
Marc Short explains why Republicans could face real challenges heading into the midterms despite recent political momentum. He also breaks down why control of the…
Thought Leader: Marc Short, Mark Halperin
Scott Gottlieb on FDA’s New Rare Disease Framework
Thought Leader: Scott Gottlieb
Scott Gottlieb: Market Dynamics and Drug Innovation
Thought Leader: Scott Gottlieb
